01—Abstract
Summary
Summary of the 8-K filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Amgen's Q2 2024 results (filed August 6, 2024) showed strong top-line growth but a sharply lower GAAP profit picture, driven primarily by the Horizon Therapeutics acquisition.
Total revenues rose 20% to $8.4 billiona, with product sales up 20% to $8.0 billion. Excluding Horizon, product sales grew 5%, with volume growth of 10%. Growth was led by newer launches and franchises such as TEZSPIRE, EVENITY, Repatha, and TEPEZZA, while Enbrel, Otezla, and the established biologics declined.
Twelve products grew at least double digits in the quarter. Profitability diverged sharply between GAAP and non-GAAP measures. GAAP diluted EPS fell 46% to $1.38b from $2.57, and GAAP operating margin dropped 16.5 points to 23.7%, largely because of roughly $1.8 billion of acquisition-related amortization and inventory step-up charges in cost of sales.
Non-GAAP EPS was nearly flat at $4.97c versus $5.00, and non-GAAP operating margin declined 4.4 points to 48.2%, reflecting incremental Horizon operating costs and higher interest expense. Investors should weigh the non-GAAP figures against the large, recurring noncash amortization that the company excludes. Cash generation and balance sheet were mixed.
Free cash flow fell to $2.2 billiond from $3.8 billion, mainly because federal tax payments shifted from Q4 2023 into Q2 2024, so the decline is largely timing. Management reduced debt by $1.4 billion in the quarter and $2.0 billion year to date, and reaffirmed its target of more than $10 billion of debt reduction by the end of 2025.
Total debt remained high at $62.6 billion against $9.3 billion of cash and investments. Full-year 2024 guidance was updated, with revenue of $32.8–33.8 billion and non-GAAP EPS of $19.10–20.10.
02—Key points
Key Highlights
- Total revenues up 20% YoY to $8.4B; product sales up 20% to $8.0B, but only 5% excluding Horizon, with 10% volume growth ex-Horizon.
- GAAP diluted EPS fell 46% to $1.38 (from $2.57) and GAAP operating margin fell 16.5 points to 23.7%, driven by Horizon-related amortization and expenses.
- Non-GAAP diluted EPS was roughly flat at $4.97 (vs. $5.00) and non-GAAP operating margin declined 4.4 points to 48.2%, reflecting Horizon costs and higher interest expense.
- Free cash flow declined to $2.2B from $3.8B, largely due to the timing of federal tax payments moving from Q4 2023 into Q2 2024.
- Debt reduced by $1.4B in Q2 and $2.0B year to date; management reiterated a target of over $10B of debt reduction by end-2025. Debt outstanding was $62.6B at June 30, 2024.
- Strong growth from newer products: TEZSPIRE (+76%), EVENITY (+39%), Repatha (+25%), TAVNEOS (+137%), and BLINCYTO (+28%), while Enbrel (-15%), MVASI (-20%), and established products (-21%) declined.
- FY2024 guidance updated: total revenue $32.8–33.8B, GAAP EPS $6.57–7.62, non-GAAP EPS $19.10–20.10, capex about $1.3B, and share repurchases up to $500M.
03—Questions
Frequently Asked Questions
Why did GAAP EPS drop so much while non-GAAP EPS was nearly flat?
GAAP results include large noncash charges tied to the Horizon acquisition, mainly amortization of acquired intangibles and inventory step-up, which totaled about $1.83B in cost of sales in Q2 2024. Amgen excludes these items from non-GAAP results, so the gap reflects acquisition accounting rather than underlying cash operations. Investors should still consider these amortization charges a real economic cost of the acquisition.
Is the Horizon acquisition performing as expected?
Horizon-acquired products contributed substantially to revenue, including TEPEZZA ($479M), KRYSTEXXA ($294M), UPLIZNA ($92M), TAVNEOS ($71M), and ultra-rare products ($187M). However, excluding Horizon, product sales grew only 5%, and non-GAAP operating margin fell 4.4 points, so the deal's accretion depends on continued launch growth and cost synergies that the filing does not quantify.
Why did free cash flow decline by about 42%?
The decline was primarily timing-related. Federal tax payments, including the repatriation tax, were made in Q4 2023 but in Q2 2024. Operating cash flow fell to $2.5B from $4.1B for the same reason. Full-year cash flow should be a better gauge of underlying performance than this single quarter.
How is Amgen managing its debt load?
Amgen has reduced debt by $2.0B year to date, from $64.6B at year-end 2023 to $62.6B at June 30, 2024, and targets more than $10B of debt reduction by the end of 2025. With cash and investments of $9.3B, deleveraging depends mainly on operating cash flow, so the pace of tax payments and product growth will matter for progress.
What are the key pipeline catalysts for the rest of 2024?
Key catalysts flagged include MariTide Phase 2 obesity topline data in late 2024, the Phase 3 CodeBreaK 300 PDUFA date of October 17, 2024 for LUMAKRAS plus Vectibix in colorectal cancer, the TEZSPIRE Phase 3 readout in chronic rhinosinusitis with nasal polyps, the rocatinlimab HORIZON Phase 3 readout in atopic dermatitis, and the UPLIZNA MINT Phase 3 readout in myasthenia gravis, all expected in H2 2024.
04—Continue